HLTH 101 Lecture Notes - Case Fatality Rate, Entry Inhibitor, Hemolytic Anemia
16 Oct 2011
School
Department
Course
Professor
Document Summary
Decline in deaths/new cases since 2005 (not in all regions) Treatment: reverse transcriptase inhibitors (prevent multiplication) ie. azt (azidothymidina) Nucleotide (act on dna) and non-nucleotide inhibitors (act on enzyme) Reduce reassembly, temporary resistance: aids cocktails. Resistance from mutation is less effective as different drugs can combat different mutations. Integrase inhibitors (blocks activation of integrase which injects virus injected dna. When to start haart: 1990"s: at start of aids symptoms. Today: early at infection, before symptoms reduces concentration of virus in body (viral load) Could reduce transmission as result (less virus in bodily fluids) Expensive (more than 000/year) (not effective in developing countries) Increased resistance due to new strains; harder to develop vaccines. In future, hopefully more prevention emphasis, possibly new resistant strains. First 18-72 hours: cold symptoms, muscle pain, congestion, fever. Virus replicates in respiratory epithelial cells resulting in cell death. Viral coat: 2 glycoprotein antigens: hemglutinin (15 known subtypes: h1-h15, neuraminidase (9 known subtypes: n1-n9)
